SLU-PP-332: Benefits, Dosage, Side Effects & Research

In late 2023, headlines promised a pill that delivers the benefits of a workout without the workout. The compound behind that wave of coverage was SLU-PP-332, and the excitement was earned. Mice given it ran dramatically farther, burned more fat, and lost weight without eating less or moving more.

Then the fine print: every one of those results came from rodents. There is still not a single published human trial on SLU-PP-332. That gap, real and exciting animal data on one side and almost no human evidence on the other, is the whole story, and it is the part most pages selling the compound skate right past.

We will be straight with you up front. We like this compound at BrainFlow. The mechanism is one of the most interesting things to come out of metabolic research in years, and the preclinical results are stacking up fast. We are also not going to pretend mouse data is human proof. This is the grounded breakdown: what SLU-PP-332 actually is, the benefits researchers are chasing, how ERR agonism works, what the studies show, the protocols people run, the safety unknowns, where it stands legally, and how it compares to GLP-1 drugs and the older exercise mimetics.

What Is SLU-PP-332?

SLU-PP-332 is a synthetic small molecule that activates the estrogen-related receptors, a trio of proteins called ERRα, ERRβ, and ERRγ. It is not a peptide, even though you will find it on peptide vendor shelves and all over peptide forums. Chemically it has nothing in common with BPC-157 or tesamorelin. It just happens to get sold in the same corner of the internet.

The name gives away its origin. “SLU” stands for Saint Louis University, where it was developed in the lab of Dr. Thomas Burris with medicinal chemist Dr. Bahaa Elgendy. The “332” is just a catalog number. Biohackers have nicknamed it “SLOOP.”

It gets called an “exercise mimetic,” meaning a compound designed to reproduce some of the cellular signals of training without the training itself. In SLU-PP-332’s case, the target is the metabolic machinery inside your muscle cells. When Burris described the early findings in University of Florida coverage in 2023, he put it plainly: the compound tells skeletal muscle to make the same changes you would see during endurance training, and the animals start using fat for fuel and losing weight.

That is the hook that made it go viral. Here is what researchers and the community are actually chasing with it, all of it currently grounded in animal and mechanistic data:

• Increased endurance and stamina through a shift toward oxidative, fatigue-resistant muscle fibers
• Fat loss without appetite suppression by raising energy expenditure rather than cutting how much you eat
• Better metabolic health, including improved insulin sensitivity and glucose handling in metabolic-syndrome models
• More mitochondria and better mitochondrial function, the cellular engines that power everything from muscle to brain
• Cardiac support, since the heart is an energy-hungry muscle that ERR activation appears to help fuel
• Healthy-aging potential, tied to reversing the mitochondrial decline that comes with getting older

Every item on that list is a legitimate research direction with published animal work behind it. Not one has been confirmed in a human yet. That combination, real science and real unknowns, is exactly why it is worth understanding properly instead of through hype or dismissal.

Because it is almost always run orally, it shows up as capsules rather than the powders most research compounds come in. Paramount Peptides carries it as tested 250 mcg and 1 mg capsules with a batch-specific certificate of analysis on every lot, which is the rare case where you can actually verify what you are getting before you research it. Code BRAINFLOW saves 10%.

Why BrainFlow Is Paying Attention

We look at a lot of research compounds. Most are recycled SARMs with a new name, or peptides with a single thin study and a mountain of marketing. SLU-PP-332 is different, and that is worth saying clearly.

It came out of a real academic lab with a named medicinal chemist behind it, not an anonymous overseas supplier. The target it hits, the ERR and PGC-1α system, is the actual molecular hub that exercise works through, which means the mechanism is not a marketing story bolted on after the fact. And the preclinical wins are not limited to one outcome. The same compound has shown effects on endurance, fat loss, blood sugar, the heart, and the aging kidney across separate, independent studies. That breadth is unusual and it is the sign of a target that truly matters.

So the enthusiasm is real on our end. If SLU-PP-332 or one of its next-generation analogs ever clears human trials, it could become a serious tool for fat loss, performance, and the kind of people who cannot exercise their way to better metabolic health. That is a big if, and the honest caveats below are not us hedging for the sake of it. They are the reason a smart researcher pays attention now instead of getting burned later.

ERR Receptors, Without the Jargon

Here is the single most misunderstood thing about this compound, and getting it right matters.

Estrogen-related receptors are not estrogen receptors. They picked up the “estrogen-related” name decades ago only because their protein structure looks similar to the estrogen receptor under a microscope. They are not switched on by estrogen, they do not bind estrogen, and activating them does nothing hormonal in the way people fear. SLU-PP-332 is not an estrogen, an anti-estrogen, or anything in that conversation.

What ERRs actually do is run energy metabolism. They are “orphan” nuclear receptors, meaning scientists have never found a natural hormone that activates them, and they concentrate in the most energy-hungry tissues you have: skeletal muscle, the heart, brown fat, and the brain. Their main job is governing the mitochondria, the parts of your cells that turn food and oxygen into usable energy.

The three subtypes split up the work. ERRα is everywhere and dominates in muscle and heart. ERRβ and ERRγ are more specialized. All three lean on a master switch called PGC-1α, the same coactivator your body ramps up when you exercise. Foundational work published in PNAS back in 2004 showed ERRα is the gear through which PGC-1α drives the creation of new mitochondria. Exercise pushes that PGC-1α and ERR system hard, which is exactly why a drug that flips the ERR switch is, on paper, an exercise mimetic.

That is the elegant part. A single compound aimed at the master regulator of cellular energy, instead of a downstream symptom. It is also why the upside, if it translates, is so broad. Touch the mitochondria and you touch endurance, fat burning, blood sugar, and cardiac function all at once.

How SLU-PP-332 Works

SLU-PP-332 is a pan-ERR agonist, meaning it activates all three receptors, with the strongest grip on ERRα. When it binds, it recruits PGC-1α and switches on the gene program your muscles run during an aerobic workout.

In the animal work, that translated into a cascade of effects: more mitochondrial activity, a shift in muscle toward the oxidative “endurance” fiber type, and a measurable change in fuel use. Within a couple of hours of dosing, treated mice shifted toward burning fat for energy, the same metabolic state you reach during fasting or a long run. Whole-body energy expenditure went up. Fat accumulation went down.

The original characterization came out of Saint Louis University in a 2023 paper in ACS Chemical Biology, where mice given SLU-PP-332 ran roughly 70% longer and about 45% farther than untreated mice. The effect depended on ERRα specifically, which nailed down the mechanism rather than leaving it as a guess. That is a clean, mechanistically grounded result, and it is the foundation everything else is built on.

What nobody can tell you yet is how any of this behaves in a human body. The compound’s oral absorption is debated, its human half-life has never been published, and its long-term effects are unstudied. The mechanism is elegant and, for now, almost entirely preclinical.

SLU-PP-332 Benefits, One by One

The bullet list above is the quick version. Here is what each benefit actually rests on, and how strong the evidence really is.

Endurance and Stamina

This is the headline effect and the strongest signal in the whole file. In the 2023 ACS Chemical Biology work, sedentary mice that had never trained ran significantly longer and farther after dosing, with their muscle taking on the molecular profile of an endurance athlete. The compound essentially convinced untrained muscle that it had been doing cardio. For anyone interested in aerobic capacity, that is a thrilling proof of concept. The asterisk never moves, though: this was measured in mice on a treadmill, not people on a track.

Fat Loss Without Cutting Food

This is the benefit that gets the most attention, and for good reason. A 2024 study in the Journal of Pharmacology and Experimental Therapeutics gave the compound to obese mice and saw roughly 12% body weight loss with improved insulin sensitivity. The standout detail is that the mice did not eat less. The weight came off through higher energy expenditure and fat oxidation, not appetite suppression.

That mechanism is the opposite of how GLP-1 drugs work, and it is why people are so interested. A compound that raises the calories you burn rather than slashing the calories you want is a different and complementary lever. In an animal, it worked. In a human, it is untested.

Metabolic and Blood Sugar Health

Improved insulin sensitivity showed up alongside the fat loss in the metabolic-syndrome mice. Since ERR activation pushes tissues to burn fuel more efficiently, better glucose handling is a logical downstream effect, and the animal data supports it. This is the angle that makes researchers think about type 2 diabetes and metabolic disease down the line, well before any of that is established.

Cardiac Support

The heart is the most mitochondria-dense muscle in the body, and a failing heart is essentially energy-starved. A 2024 paper in Circulation tested SLU-PP-332 and a next-generation analog in mice with induced heart failure and found improved cardiac function and survival. It is one of the more striking findings, because it points at a therapeutic use far beyond aesthetics. It is also early-stage animal work, and the heart is exactly the organ where you want human safety data before getting comfortable.

Healthy Aging and Recovery

Mitochondrial decline is one of the core drivers of aging, so a compound that restores mitochondrial function has obvious longevity appeal. Work in the American Journal of Pathology in 2023 showed ERR agonism reversed mitochondrial dysfunction and inflammation in the aging kidneys of old mice. Community members also report faster recovery between hard sessions, plausibly tied to the same mitochondrial uplift, though that piece is anecdotal rather than studied.

Put together, the benefit profile is broad and mechanistically coherent, which is rare and genuinely exciting. The honest grading looks like this:

Common Dosing Protocols

This is the section people skip to, so let us be useful and honest at the same time. There is no clinically established human dose for SLU-PP-332, because there are no human trials. What follows is a map of what the research community actually does and where those numbers come from, not a prescription.

The Micrograms vs Milligrams Split

The forums divide into two camps that cannot both be right. The first talks in micrograms, roughly 250 mcg to a few milligrams per day. Those numbers are essentially reverse-engineered from the capsule sizes vendors happen to sell. The second camp scales up the mouse studies, which used 25 to 50 mg/kg by injection, and lands on hundreds of milligrams a day.

The second approach is a trap. You cannot take a mouse mg/kg dose and convert it straight to a human. Body-surface-area scaling, species metabolism, and unknown human oral absorption all break the math, and naively copying the rodent dose would put you into hundreds of milligrams of an untested compound with no safety basis whatsoever. The microgram camp is the more conservative starting point that most oral users actually follow.

What an Oral Protocol Usually Looks Like

Almost everyone runs SLU-PP-332 orally, which is why capsules dominate. The commonly described pattern goes like this. People start low, often a single 250 mcg capsule per day, to gauge tolerance. From there, some hold steady while others titrate up toward 500 mcg or 1 mg daily over a week or two, watching for the subjective signs they are after, more sweating, easier cardio, a leaner look.

Daily dosing is the norm rather than every-other-day, and most reports describe taking it in the morning or 30 to 60 minutes before cardio, on the theory that the fat-oxidation shift pairs with training. Whether timing actually matters in humans is unknown, since the human half-life has never been measured. Vendor pages throw around figures from 1.5 to 16 hours, none of it from a published human study, so treat all of it as guesswork.

Cycle Length

Run lengths discussed online cluster around 8 to 12 weeks, followed by a break of similar length. The reasoning is partly borrowed from how people cycle other research compounds and partly common sense: you are chronically activating receptors central to cardiac and mitochondrial function, and no one has studied what continuous long-term use does in a person. A defined on-and-off structure is the cautious instinct, not an evidence-based protocol.

What People Watch For

The single most common report is feeling nothing on capsules, which loops back to the oral-absorption debate. Beyond that, the prudent approach people describe is keeping the dose at the low end, not stacking it with stimulants or other metabolic compounds while assessing it, and stopping entirely if anything feels off cardiovascularly. Higher is not better here. Overshooting the dose is a plausible route to more risk, not more benefit.

SLU-PP-332 vs the Alternatives

People rarely look at SLU-PP-332 in isolation. They want to know how it compares to the things that already work and to the compounds it gets shelved next to. The short answer is that it solves a different problem than most of them, which is part of what makes it interesting.

Against the GLP-1 drugs (semaglutide, tirzepatide, retatrutide), it is not even the same category. Those are appetite drugs with massive human trial data and FDA approval, and they drive weight loss by making you eat less. SLU-PP-332 is an energy-expenditure idea that, in mice, worked without touching appetite. Different lever entirely. In theory the two approaches could one day be complementary, but only one of them is proven in people today.

The more telling comparison is to the older exercise mimetics, and this is where SLU-PP-332 actually looks good. Cardarine (GW501516) generated the same buzz years ago and was abandoned after long-term rodent studies showed it caused cancer across multiple organs. SR9009 (Stenabolic) is famous for barely absorbing when taken orally. SLU-PP-332 is newer, hits a cleaner target, and so far has not carried the cancer baggage that sank Cardarine. It still shares the family caveat: spectacular in mice, unproven and unapproved in humans.

If your goal is fat loss with evidence behind it right now, the order is exercise and diet first, then the FDA-approved drugs, then research peptides with at least some human signal, and then animal-stage compounds like this one. SLU-PP-332’s spot on that ladder will climb fast if human data ever lands. For now it sits where the science honestly places it.

The “Exercise in a Pill” Problem

The phrase that sold this compound is also the phrase that oversells it. Calling anything “exercise in a pill” assumes a workout is one thing happening in one place. It is not.

SLU-PP-332 nudges a single lever: the ERR and PGC-1α pathway inside muscle that governs mitochondria and fat burning. Training pulls that lever too, but it pulls dozens of others at the same time. Lifting and running load your bones and connective tissue so they get denser and stronger. Cardio remodels your heart and blood vessels. Movement sharpens neuromuscular coordination, improves whole-body insulin sensitivity in ways a single receptor cannot, and reliably lifts mood and sleep. No ERR agonist touches most of that.

Where the science is most exciting is for people who cannot exercise: the frail elderly, those with muscle-wasting disease or serious mobility limits. Reproducing even part of the muscle-metabolism benefit in that population would be a major win, and it is a legitimate reason the research is moving. For a healthy person who could just go for a run, the compound mimics the one adaptation it targets while skipping everything else exercise does for you. Best case, it is a powerful complement to training, not a replacement for it.

Side Effects and Safety

The truthful headline is that nobody knows the human safety profile, because the human studies do not exist. What we have is short-term mouse data, and it was reassuring for mice.

The early studies reported no overt toxicity, normal blood counts, and no muscle-damage markers over their dosing windows. Burris noted in the press that the compound had not produced severe side effects in the animals. That is encouraging, and it is also a very low bar for something people are putting in their bodies daily. Short-term and in a mouse is not the same standard as long-term and in a human.

Anecdotally, users describe more sweating and body heat, a drier or leaner look on a cut, and clean energy without a stimulant crash. The most common report, though, is nothing at all, which points back to the oral absorption question.

The theoretical concerns are worth naming plainly. ERRs are central to how the heart manages energy, and chronically activating them with a drug is being explored as both a potential heart-failure treatment and an unknown long-term risk. Pushing mitochondria hard over months in healthy people has never been studied. And there is precedent for caution: Cardarine looked clean and exciting until a two-year rodent study showed it driving cancer across several organs. Exercise-mimetic enthusiasm has burned people before, which is why we stay enthusiastic and careful at the same time.

One risk you can actually control is what is in the capsule. This is a grey-market research chemical, so purity, identity, and accurate dosing are not guaranteed unless the source provides third-party testing. A batch-specific certificate of analysis is the floor, not a luxury, which is the practical case for sticking with a tested supplier rather than the cheapest listing you can find.

Anyone with a cardiovascular condition, anyone pregnant or breastfeeding, and anyone on interacting medications has every reason to stay away from an untested compound like this. So does any drug-tested athlete, for reasons in the next section.

Is SLU-PP-332 Legal?

SLU-PP-332 is not an FDA-approved drug for weight loss, performance, or anything else. It is also not a lawful dietary supplement ingredient, so it cannot be legally sold for human consumption. What you see online is the research-use-only market, where “for research use only” is a liability label, not a stamp of safety or quality.

For anyone subject to drug testing, treat it as off-limits. It is not yet named on the WADA prohibited list, but anti-doping labs have already published methods to detect it, including work in the journal Drug Testing and Analysis in 2026. It also sits in the same conceptual family as the banned metabolic modulators like Cardarine and SR9009, and anti-doping rules include catch-all language for substances with similar effects and for non-approved compounds. The safe assumption for a tested athlete is that it is prohibited.

One more practical note: the FTC goes after exaggerated weight-loss and performance claims, so the breathless “burn fat without exercise” marketing around this compound is exactly the kind of thing that draws regulatory attention. Loud claims are a reason for more skepticism, not less.

What People Actually Report

Forum sentiment is not evidence, but it is useful for setting expectations, so here is the pattern across peptide and biohacking communities.

The positive reports center on endurance and a leaner look: easier zone 2 cardio, more sweating, a “dried out” appearance on a cut. The skeptical reports are just as common, and they cluster around one theme, that oral capsules often do nothing noticeable. The community splits between “feels like a mild Cardarine” and “I felt absolutely nothing,” which is exactly what you would expect from a compound with a real debate about whether it even absorbs by mouth.

The recurring questions are always the same: is it a peptide (no), oral or injected (mostly oral), what is the half-life (unknown), and is the grey-market product even real (depends entirely on the source). The recurring misconception is treating those mouse weight-loss numbers as if they will show up the same way in a person. They might show up smaller, or not at all.

Where to Buy SLU-PP-332

This is where most of the real-world risk lives. SLU-PP-332 is a grey-market research chemical, which means the gap between a clean, accurately dosed product and a mislabeled or contaminated one is entirely on the vendor. Independent testing of research compounds routinely turns up products that are underdosed, impure, or not even the right molecule, and you have no way to know which you bought without a certificate of analysis.

Two things matter most when sourcing it. First, third-party verification: a batch-specific COA showing purity by HPLC and mass spectrometry. Second, format, since this compound is run orally and pre-measured capsules remove the guesswork and the mess of weighing raw powder.

That is why we point readers to Paramount Peptides for the capsule route. They synthesize in-house in Southern California, have operated for over a decade, verify at 99%+ purity with batch COAs, and sell SLU-PP-332 in both 250 mcg and 1 mg capsules so you can match the strength to the range you are researching. They do require a free account to view pricing, which is standard for this category.

Frequently Asked Questions

Is SLU-PP-332 a peptide?

No. It is a synthetic small molecule that activates the estrogen-related receptors. It gets sold and discussed alongside peptides like MOTS-c and tesamorelin, which is why the confusion is so common, but chemically it is a different class entirely.

Does SLU-PP-332 work for weight loss in humans?

There is no human evidence either way. In obese mice it produced about 12% weight loss without reducing food intake, which is an exciting result, but no human trial has ever tested it. Anyone presenting it as a proven human fat-loss tool is extrapolating from rodents.

Is it really “exercise in a pill”?

That phrase oversells it. SLU-PP-332 mimics one slice of what exercise does, the muscle-metabolism and mitochondrial signaling, and only in animals so far. It does nothing for your bones, heart conditioning, coordination, or the broad health effects of actually moving. Think complement to training, not replacement.

Is SLU-PP-332 an estrogen or does it affect hormones?

No. Estrogen-related receptors only share a structural resemblance to estrogen receptors. They are not activated by estrogen and have nothing to do with estrogenic or anti-estrogenic effects. They regulate energy metabolism, not reproductive hormones.

What is a common SLU-PP-332 dose?

Online discussion ranges from about 250 mcg to a milligram or more daily by capsule, usually run for 8 to 12 weeks. Those numbers come from vendor sizes and forum convention, not human studies. There is no established human dose, and nothing here is a dosing recommendation.

Why do some people say it does nothing?

The parent compound’s oral bioavailability is debated, and “felt nothing on capsules” is one of the most common reports. The researchers themselves developed follow-up analogs partly to improve oral absorption, which suggests the original molecule may not absorb well by mouth.

Is SLU-PP-332 FDA-approved?

No. It is not approved as a drug, it is not a legal dietary supplement, and it is sold only as a research compound. It is years away from human approval, if it ever gets there.

Is it banned in sport?

It is not specifically named yet, but anti-doping labs have already built tests for it, and it falls under the same metabolic-modulator family as banned compounds plus the catch-all rules for non-approved substances. A tested athlete should treat it as prohibited.

How does it compare to Cardarine or SR9009?

All three are exercise-mimetic research compounds with strong animal data and weak or absent human data. SLU-PP-332 hits a different and arguably cleaner target (ERR rather than PPARδ or REV-ERB) and has not carried Cardarine’s cancer signal so far, but it shares the same core caveat: impressive in mice, unproven and unapproved in people.

Where does the “ran 70% farther” claim come from?

From the 2023 Saint Louis University study in ACS Chemical Biology, where treated mice ran roughly 70% longer and 45% farther on a treadmill. It is a real, peer-reviewed finding, and it is a finding about mice.

Final Verdict

SLU-PP-332 is one of the most genuinely exciting compounds in the metabolic research space, and we are not going to pretend otherwise. The biology is sound, the lab pedigree is real, and the preclinical wins across endurance, fat loss, blood sugar, the heart, and aging are the kind of breadth you almost never see this early. A real research effort is pushing it and its analogs forward, which puts it in a different league from the average grey-market chemical.

What it does not have yet is the one thing that would justify the full hype: a human trial. Not one has been published. The weight-loss and endurance numbers everyone quotes are mouse numbers, the oral version may not absorb well, the long-term safety is a blank page, and it is neither approved nor legal to sell for human use. Those are not footnotes. They are the reason to watch this one closely rather than go all-in.

If you are a researcher or an early adopter who understands you are working with an animal-stage compound, source matters enormously, and the capsule formats from Paramount Peptides at least take purity and dosing accuracy off the worry list. Code BRAINFLOW saves 10%. For everyone else, the most reliable version of what SLU-PP-332 promises is still the free one: train, eat well, sleep. This is a compound we are watching closely and rooting for. Just do not mistake promising for proven, because right now it is squarely the former.

Related Reading

• The Best Peptides for Weight Loss in 2026
• MOTS-c: The Mitochondrial Peptide, Benefits and Dosage
• Tesamorelin Guide: Benefits, Dosage, and Side Effects

SLU-PP-332 is an experimental research compound. It is not FDA-approved for weight loss, performance, endurance, or any medical use, and it is not a dietary supplement. All information in this article is provided for educational purposes only and does not constitute medical advice. Nothing here is a personal dosing recommendation.

SLU-PP-332 is sold as a research compound for laboratory use only and is not intended for human consumption. Consult a qualified healthcare professional before beginning any new protocol.

This article contains affiliate links to Paramount Peptides. BrainFlow may earn a commission on qualifying purchases at no additional cost to the reader. We only recommend sources we trust.